The result landed on August 19, and the market's first response was to hand the entire prize to Moderna. In a late-stage trial called INTerpath-001, 1,137 patients with high-risk melanoma whose tumors had been surgically removed were treated with Moderna's personalized mRNA vaccine, intismeran autogene, in combination with Merck's pembrolizumab, or with pembrolizumab alone. The combination met the trial's primary endpoint of recurrence-free survival, and it met the key secondary endpoint of distant metastasis-free survival, with no new safety signals. It was the first positive Phase III readout ever for an individualized neoantigen therapy and the first for an mRNA cancer therapy.
Moderna's stock doubled in a day. Short sellers, who had made the company the most-shorted stock in the S&P 500, lost roughly $5 billion in a single session, according to S3 Partners. But the durable meaning of the trial sits somewhere the stock chart does not show. The company that paid for the breakthrough does not get to keep most of what it proves.
The doubt was the default position
It is worth remembering how unlikely this outcome looked even to the people closest to it. STAT's account of the trial's history, by Matthew Herper, Jason Mast, and Angus Chen, opens with a scene from a Moderna leadership off-site in March 2023, after mid-stage results had begun to look promising: chief executive Stéphane Bancel asked roughly 100 executives whether any of them had expected the cancer vaccine to succeed. President Stephen Hoge, on stage at the time, sat down. Then Bancel sat down. Hoge later recalled thinking, "Oh my gosh. This is real."
The external doubt was if anything more aggressive. By mid-2026, roughly 17.8 percent of Moderna's float was sold short, the highest short interest in the S&P 500 according to Bank of America. The bear case was not irrational. U.S. Covid vaccine revenue had fallen to about $1.2 billion in 2025 and was guided toward roughly $1 billion in 2026, and the company was burning cash across a pipeline of unproven programs, targeting cash breakeven only by 2028. Before the readout, the consensus analyst rating sat at Reduce, with an average price target below the stock price. The market's model of Moderna was a company whose great product was in the past, and the shorts were a bet on exactly that.
The trial was built to end the argument
The design of INTerpath-001 reads like a document written against the skeptics. Patients were randomized two to one to receive intismeran autogene, one milligram every three weeks for up to nine doses, alongside pembrolizumab at 400 milligrams every six weeks for up to nine cycles, roughly a year of treatment, against pembrolizumab alone. The primary endpoint was recurrence-free survival, with distant metastasis-free survival as the key secondary measure, and overall survival will keep accruing per protocol. The Phase IIb predecessor, KEYNOTE-942, reported at five-year follow-up this year, showed the combination reduced the risk of recurrence or death by 49 percent, with a hazard ratio of 0.51, and the risk of distant metastasis or death by 59 percent, a hazard ratio of 0.411. The Phase III was not built to confirm a small effect. It was built so that a win could not be argued away.
The cost was concentrated on the believers
The trial itself was a gauntlet designed to make the skeptics' case hard to dismiss. The comparator was pembrolizumab alone, which is the standard of care for resected high-risk melanoma. The vaccine had to beat the best available drug, not a placebo. And the product is not a vial off a shelf: each dose is manufactured for one patient, built from sequencing of that patient's tumor to select up to 34 patient-specific mutations, encoded in synthetic mRNA to train immune cells against the cancer's own fingerprints. The logistics of making an individualized drug for the vaccinated patients across the trial, under pandemic-era disruption and clinical-grade timelines, were themselves a major unproven proposition.
Moderna carried that cost, financially and operationally, through years in which its stock was treated as a decaying Covid franchise. Even so, the market priced the stock as though the company's future was mostly its past. The Phase III readout is the moment the pricing changed.
The benefit is diffuse, and most of it lands elsewhere
Look at where the value of this result actually flows. Merck's stock rose about 13 percent to a record high on the news. Merck supplied pembrolizumab, the backbone drug of the combination, and pembrolizumab is the franchise of record in cancer immunotherapy. Every patient treated with the combination is a patient on Merck's drug, and the adjuvant melanoma setting is a market pembrolizumab alone already leads. The vaccine does not replace the backbone; it attaches to it. The larger commercial stream from any approval flows through the established franchise, and Merck keeps the dominant share of that stream.
Then there is the rest of the field. BioNTech, the other standard-bearer of mRNA, was handed the same validation without spending for it, and its own programs now inherit the reduced cost of credibility. The single most valuable thing the trial proved is not about one product. It is that mRNA-based individualized cancer vaccines, as a category, can clear the highest evidentiary bar in oncology. Every company working on the same platform, from BioNTech downward, was handed a proof of concept it did not have to pay for. Investors can now underwrite mRNA oncology programs on a demonstrated path rather than a hypothesis. Patients with other tumor types gained a reason to expect the nine additional Phase II and III trials in the INTerpath program, across lung, bladder, and kidney cancer, to be worth completing.
Even the skeptics left with something: the trial continues for overall survival, and the companies disclosed no hazard ratios or event rates in the topline, so the cautious demand for full data remains a fair one. The point is not that every question is settled. The point is that the questions now being asked are about magnitude and durability, not about whether the approach can work.
What the triumph does not settle for Moderna itself
The irony is that the win does the least for the company most identified with it, at least in the near term. The cancer vaccine program is shared with Merck, whose drug is the commercial center of gravity. Moderna's own business is still the shrinking respiratory franchise, and a single successful oncology asset, however historic, does not by itself fund a pipeline or fix a burn rate. The company still faces the same questions about Covid revenue, about the standalone flu vaccine, about cash breakeven, and about execution across a sprawling portfolio. The stock's surge repriced the optionality. It did not rebuild the revenue base.
The company's near-term economics remain what they were. U.S. Covid vaccine revenue is guided down roughly 20 percent for 2026, toward $1 billion, against a business that once carried the whole company. Growth, if it comes, comes from elsewhere: contracts with the United Kingdom, Canada, and Australia that lift international revenue from about $700 million toward $1 billion, a European respiratory market that opens in 2027, and the pipeline's other late-stage bets, including the norovirus vaccine readout and the U.S. flu vaccine decision that came due this month. The cancer vaccine is the headline, but the cash problem was never cancer-shaped. And the program's breadth is now the field's roadmap: nine Phase II and III trials across melanoma, lung, bladder, and kidney cancer, each an experiment the skeptics said was premature, now running on the strength of the first definitive answer.
The deeper transfer, though, runs in the opposite direction from what the one-day price action implied. First movers in a new drug class pay to build the road: the trials, the manufacturing science, the regulatory template, the standard of evidence. Then the road is public. The personalized cancer vaccine category now has a demonstrated road, and the marginal value of proving it again, for any competitor, has fallen toward zero. What Moderna bought with a decade of spending and doubt was not a monopoly on mRNA cancer therapy. It was the option to stand in front of the field, and options, once exercised, stop being options.
The win is bigger than the company
Moderna and Merck will file, seek approval, and, if all goes well, treat patients, with availability possible in 2027 given the breakthrough therapy designation. But the trial's largest consequence is that mRNA oncology moved from hypothesis to asset class on August 19. The company whose name sits on the vaccine will keep a share of what follows. It cannot keep the fact of the proof, because the proof, by its nature, belongs to everyone now. The shorts who lost $5 billion were right about Moderna's past and catastrophically wrong about the value of what the company was carrying into the future. The market's instinct was to pay for the news. The news itself was worth more than any one company could be paid for it.
Primary sources
- STAT's reporting by Matthew Herper, Jason Mast, and Angus Chen for the narrative of the trial's history, the March 2023 leadership scene, and Stephen Hoge's recollection.
- The ASCO Post and the Pharmaceutical Journal's coverage of Merck and Moderna's announcement for the trial design, endpoints, topline results, and the KEYNOTE-942 five-year figures.
- Short interest data from Bank of America and the one-day short loss estimate from S3 Partners, via financial press coverage of Moderna's revenue guidance and analyst consensus.